| Name | (2S)-2-Hydroxy-3-methyl-N-[(2S)-1-{[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]amino}-1-oxo-2-propanyl]butanamide |
|---|---|
| Synonyms |
Butanamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-hydroxy-3-methyl-, (2S)-
(2S)-2-Hydroxy-3-methyl-N-[(2S)-1-{[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]amino}-1-oxo-2-propanyl]butanamide LY900009 |
| Description | LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibited Notch signalling in tumor cell lines and endothelial cells (IC50 range: 0.005-20 nM). LY900009 can be used for advanced cancer research[1]. |
|---|---|
| Related Catalog | |
| In Vivo | 在大鼠模型中,LY900009 (口服灌胃;3 mg/kg;单剂量) 通过形成渗漏脉管系统抑制血管生成,并在 Notch 依赖性肿瘤模型中导致肿瘤消退[1]。 |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 781.5±60.0 °C at 760 mmHg |
| Molecular Formula | C23H27N3O4 |
| Molecular Weight | 409.48 |
| Flash Point | 426.5±32.9 °C |
| Exact Mass | 409.200165 |
| LogP | 3.97 |
| Vapour Pressure | 0.0±2.8 mmHg at 25°C |
| Index of Refraction | 1.622 |
| Storage condition | -20℃ |